{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:46:21Z","timestamp":1790678781332,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jdsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jdermsci.2020.04.004","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T20:43:36Z","timestamp":1587674616000},"page":"163-172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR\/Cas9 and piggyBac transposon system"],"prefix":"10.1016","volume":"98","author":[{"given":"Munenari","family":"Itoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Kawagoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuto","family":"Tamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidemi","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Asahina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka James","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdermsci.2020.04.004_bib0005","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jaad.2014.01.903","article-title":"Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification","volume":"70","author":"Fine","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5582\/irdr.2017.01005","article-title":"Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa","volume":"6","author":"Rashidghamat","year":"2017","journal-title":"Intractable Rare Dis. Res."},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0015","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of pluripotent stem cells from adult human fibroblasts by defined factors","volume":"131","author":"Takahashi","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0020","doi-asserted-by":"crossref","first-page":"8797","DOI":"10.1073\/pnas.1100332108","article-title":"Generation of keratinocytes from normal and recessive dystrophic epidermolysis bullosa-induced pluripotent stem cells","volume":"108","author":"Itoh","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077673","article-title":"Generation of 3D skin equivalents fully reconstituted from human induced pluripotent stem cells (iPSCs)","volume":"8","author":"Itoh","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0030","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009342","article-title":"Induced pluripotent stem cells from human revertant keratinocytes for the treatment of epidermolysis bullosa","volume":"6","author":"Umegaki-Arao","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0035","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev-genet-112414-054926","article-title":"From genomics to gene therapy: induced pluripotent stem cells meet genome editing","volume":"49","author":"Hotta","year":"2015","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0040","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.stem.2016.04.013","article-title":"Induced pluripotent stem cells meet genome editing","volume":"18","author":"Hockemeyer","year":"2016","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0045","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/jgm.486","article-title":"Excision of Sleeping Beauty transposons: parameters and applications to gene therapy","volume":"6","author":"Liu","year":"2004","journal-title":"J. Gene Med."},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0050","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/emboj.2008.41","article-title":"piggyBac can bypass DNA synthesis during cut and paste transposition","volume":"27","author":"Mitra","year":"2008","journal-title":"EMBO J."},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0055","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.scr.2016.05.003","article-title":"Integration-free T cell-derived human induced pluripotent stem cells (iPSCs) from a patient with recessive dystrophic epidermolysis bullosa (RDEB) carrying two compound heterozygous mutations in the COL7A1 gene","volume":"17","author":"Itoh","year":"2016","journal-title":"Stem Cell Res."},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0124633","article-title":"CCTop: an intuitive, flexible and reliable CRISPR\/Cas9 target prediction tool","volume":"10","author":"Stemmer","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0065","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.stemcr.2017.05.013","article-title":"Fetal therapy model of myelomeningocele with three-dimensional skin using amniotic fluid cell-derived induced pluripotent stem cells","volume":"8","author":"Kajiwara","year":"2017","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0070","article-title":"A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa","volume":"69","author":"Yan","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0075","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/bjd.12599","article-title":"Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: results of a randomized, vehicle-controlled trial","volume":"169","author":"Petrof","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0080","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1038\/jid.2008.78","article-title":"Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa","volume":"128","author":"Wong","year":"2008","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0085","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1046\/j.1523-1747.2003.12571.x","article-title":"Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the Basement Membrane Zone","volume":"121","author":"Woodley","year":"2003","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0090","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.jid.2016.02.811","article-title":"Gene-corrected fibroblast therapy for recessive dystrophic epidermolysis bullosa using a self-inactivating COL7A1 retroviral vector","volume":"136","author":"Jack\u00f3w","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0095","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1172\/JCI200317193","article-title":"Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue","volume":"111","author":"Khavari","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0100","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/mt.2013.56","article-title":"TALEN-based gene correction for epidermolysis bullosa","volume":"21","author":"Osborn","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0105","first-page":"1","article-title":"CRISPR\/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa","volume":"1","author":"Lonetree","year":"2016","journal-title":"NPJ Regen. Med."},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0110","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1016\/j.ymthe.2017.07.005","article-title":"COL7A1 editing via CRISPR\/Cas9 in recessive dystrophic epidermolysis bullosa","volume":"25","author":"Hainzl","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0115","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.omtn.2018.06.008","article-title":"Ex vivo COL7A1 correction for recessive dystrophic epidermolysis bullosa using CRISPR\/Cas9 and homology-directed repair","volume":"12","author":"Izmiryan","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0120","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.drudis.2010.01.006","article-title":"Homologous recombination in human iPS and ES cells for use in gene correction therapy","volume":"15","author":"Nakayama","year":"2010","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.3009540","article-title":"Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa (Science Translational Medicine (2014) 6 (267er8))","volume":"6","author":"Sebastiano","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0130","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1101\/gr.173427.114","article-title":"Seamless gene correction of \u03b2-thalassemia mutations in patient-specific iPSCs using CRISPR\/Cas9 and piggyBac","volume":"24","author":"Xie","year":"2014","journal-title":"Genome Res."},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0135","first-page":"1","article-title":"piggyBac transposon","volume":"3","author":"Yusa","year":"2014","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0140","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1128\/MCB.00670-12","article-title":"The piggyBac transposon displays local and distant reintegration preferences and can cause mutations at noncanonical integration sites","volume":"33","author":"Yusa","year":"2013","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0145","doi-asserted-by":"crossref","first-page":"5676","DOI":"10.1073\/pnas.1512028113","article-title":"Site-specific genome editing for correction of induced pluripotent stem cells derived from dominant dystrophic epidermolysis bullosa","volume":"113","author":"Shinkuma","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2019.07.701","article-title":"Base editor correction of COL7A1 in recessive dystrophic epidermolysis bullosa patient-derived fibroblasts and iPSCs","volume":"140","author":"Osborn","year":"2020","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0155","doi-asserted-by":"crossref","first-page":"26846","DOI":"10.1073\/pnas.1907081116","article-title":"CRISPR\/Cas9-based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells","volume":"116","author":"Jack\u00f3w","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2012.04.012","article-title":"Punch grafting of chronic ulcers in patients with laminin-332-deficient, non-Herlitz junctional epidermolysis bullosa","volume":"68","author":"Yuen","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0165","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1038\/jid.2015.158","article-title":"Potential of systemic allogeneic mesenchymal stromal cell therapy for children with recessive dystrophic epidermolysis bullosa","volume":"135","author":"Petrof","year":"2015","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0170","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.jid.2016.07.004","article-title":"Stem cell therapy for epidermolysis bullosa\u2014does it work?","volume":"136","author":"Tamai","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0175","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(13)61897-8","article-title":"Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix","volume":"382","author":"Tolar","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0180","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa0910501","article-title":"Bone marrow transplantation for recessive dystrophic epidermolysis bullosa","volume":"363","author":"Wagner","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0185","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/stem.1084","article-title":"Derivation of mesenchymal stem cells from human induced pluripotent stem cells cultured on synthetic substrates","volume":"30","author":"Villa-Diaz","year":"2012","journal-title":"Stem Cells"},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0190","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/mt.2013.71","article-title":"Generation of engraftable hematopoietic stem cells from induced pluripotent stem cells by way of teratoma formation","volume":"21","author":"Suzuki","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jdermsci.2020.04.004_bib0195","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.stem.2013.09.002","article-title":"Induction of multipotential hematopoietic progenitors from human pluripotent stem cells via respecification of lineage-restricted precursors","volume":"13","author":"Doulatov","year":"2013","journal-title":"Cell Stem Cell"}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181120301377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181120301377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T04:50:22Z","timestamp":1760331022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181120301377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0923181120301377"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2020.04.004","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR\/Cas9 and piggyBac transposon system","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2020.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}